Literature DB >> 12407575

Natural history of chronic hepatitis C.

Leonard B Seeff1.   

Abstract

Much controversy surrounds the issue of the natural history of hepatitis C virus (HCV) infection. Many authorities view the disease as inexorably progressive with a high probability of advancing over time to cirrhosis and occasionally hepatocellular carcinoma (HCC) and, therefore, likely to be responsible for causing death. Others regard chronic hepatitis C as having a variable outcome, the majority of infected persons not dying from the disease, but more likely from the comorbid conditions that so often accompany infection by this agent, or from more common medical conditions. Disagreements probably derive from the manner of conduct of the study and the populations studied. Efforts to determine natural history are handicapped by the primary characteristics of the disease, namely that its onset rarely is recognized and its course is prolonged exceedingly. Thus, different outcomes have come from retrospective rather than from prospective studies, but both have concluded that at least 20% of chronically infected adults develop cirrhosis within 20 years. More recent studies that used a retrospective/prospective approach, focusing largely on young infected individuals, have produced different results. Among these young people, particularly young women, spontaneous resolution of the viral infection is more common than previously thought and cirrhosis has been identified in 5% or fewer of them. The major failing for all groups studied, young and old, is that natural history studies have rarely exceeded the first 2 decades, so that outcome beyond this time is not known, other than through modeling. Several host-related and extraneous factors probably affect the natural history.

Entities:  

Mesh:

Year:  2002        PMID: 12407575     DOI: 10.1053/jhep.2002.36806

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  406 in total

1.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.

Authors:  A B Jazwinski; A J Thompson; P J Clark; S Naggie; H L Tillmann; K Patel
Journal:  J Viral Hepat       Date:  2011-11-24       Impact factor: 3.728

3.  Risk of myocardial infarction associated with chronic hepatitis C virus infection: a population-based cohort study.

Authors:  K A Forde; K Haynes; A B Troxel; S Trooskin; M T Osterman; S E Kimmel; J D Lewis; V Lo Re
Journal:  J Viral Hepat       Date:  2011-11-13       Impact factor: 3.728

4.  Intramolecular regulation of the sequence-specific mRNA interferase activity of MazF fused to a MazE fragment with a linker cleavable by specific proteases.

Authors:  Jung-Ho Park; Yoshihiro Yamaguchi; Masayori Inouye
Journal:  Appl Environ Microbiol       Date:  2012-03-23       Impact factor: 4.792

5.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

Review 6.  Modulation of immune responses following solid organ transplantation by microRNA.

Authors:  Nayan J Sarma; Venkataswarup Tiriveedhi; Sabarinathan Ramachandran; Jeffrey Crippin; William Chapman; T Mohanakumar
Journal:  Exp Mol Pathol       Date:  2012-10-01       Impact factor: 3.362

7.  Natural history of vertically acquired HCV infection and associated autoimmune phenomena.

Authors:  Silvia Garazzino; Carmelina Calitri; Antonella Versace; Alda Alfarano; Carlo Scolfaro; Chiara Bertaina; Simona Vatrano; Federica Mignone; Francesco Licciardi; Clara Gabiano; Pier-Angelo Tovo
Journal:  Eur J Pediatr       Date:  2014-03-04       Impact factor: 3.183

8.  Role of genetic polymorphisms in hepatitis C virus chronic infection.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Caterina Sagnelli; Lorenzo Onorato; Evangelista Sagnelli
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

9.  Peripheral CD27-CD21- B-cells represent an exhausted lymphocyte population in hepatitis C cirrhosis.

Authors:  Hiroyoshi Doi; Shiroh Tanoue; David E Kaplan
Journal:  Clin Immunol       Date:  2013-12-17       Impact factor: 3.969

10.  Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.

Authors:  Naina Barretto; Bruno Sainz; Snawar Hussain; Susan L Uprichard
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.